Navigation Links
W.M. Keck Foundation announces 2008 class of Distinguished Young Scholars in Medical Research
Date:7/28/2008

Los Angeles, CA. July 28 2008: The W.M.Keck Foundation, a leading supporter of pioneering medical research, science and engineering, today announced its 2008 class of Distinguished Young Scholars in Medical Research and Research Excellence Awardees.

Robert A. Day, Chairman and Chief Executive Officer, said: "Now in its tenth year, our Young Scholars program helps to promote the early career development of some of the country's most promising biomedical scientists.

"Over the past decade, Keck Young Scholars have consistently produced high-impact research and have advanced to become some of the most prominent scientists in their respective fields.We are proud to have helped jump-start the careers of some of our nation's research leaders and are very pleased to support a new group of young scholars who we believe have the same potential."

Under the Young Scholars program, each grant recipient's sponsoring institution receives an award of up to $1 million to support the scientist's research activities for a period of up to five years. Since its inception in 1998, the Young Scholars program has awarded 49 grants at leading research universities and institutions.

Each applicant was nominated by his or her academic institution and then evaluated individually by the Foundation's Medical Research staff and an advisory committee of outside scientific experts. The committee carefully evaluated each of the finalists and recommended the ten recipients, who were unanimously approved by the Foundation's Board of Directors.

The Foundation also recognizes the achievement of five additional young scientists with Research Excellence grants of $25,000.

Members of the 2008 class of Distinguished Young Scholars are:

  • Carl Novina, M.D., Ph.D., Assistant Professor, Cancer Immunology and AIDS, Dana-Farber Cancer Institute Dr. Novina's research focuses on identifying effectors and regulators of mammalian microRNAs, which silence genes and a
    '/>"/>

Contact: Louise Weston
lweston@longviewcomms.ca
604-694-6033
W. M. Keck Foundation
Source:Eurekalert

0

GOOD

Page: 1 2 3

Related biology news :

1. Michael J. Fox Foundation awards $2.4M for validation of therapeutic targets for Parkinsons
2. Glenn Foundation for Medical Research commits $5 million to study aging
3. BBVA Foundation Awards for Biodiversity Conservation
4. The Parkinsons Disease Foundation awards $950,000 in seed grants
5. The AGA Foundation invests in gastroenterologys future
6. European Science Foundation aims to strengthen regenerative medicine
7. National Science Foundation funds research addressing enduring questions of life
8. Spradling receives Gruber Foundation Genetics Prize for new genetic techniques
9. BBVA Foundation international study on attitudes to stem cell research
10. Landon Foundation-AACR INNOVATOR Awards
11. National Lung Cancer Partnership and LUNGevity Foundation

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/4/2009)... What,s the cost of saving a teena...ath resulting from prescription medication abuse, ..., however, may be unaware that the lock-boxes they...the ticking timebomb of prescription drugs. That,s...ity medical supplies, has formed an exclusive part...
(Date:11/4/2009)...ntists at the University of North Carolina at Chap...alifornia, San Francisco have developed and experi...diseases for existing drugs. , The researchers d...similar the structures of all known drugs are to t...s ligands -- of disease targets within the cell. I...
(Date:11/3/2009)...ember 4, 2009) For more than 25 years, all attemp...mbus gigas ) have been unsuccessfuluntil now. For ...niques to produce beaded (nucleated) and non-beade...eveloped by scientists from Florida Atlantic Unive...I). With less than two years of research and exper...
Breaking Biology News(10 mins):MEDNET Launches MedSafe to Prevent Teenage Prescription Drug Abuse 2MEDNET Launches MedSafe to Prevent Teenage Prescription Drug Abuse 3Study points to new uses, unexpected side effects of already existing drugs 2Scientists are first to 'unlock' the mystery of creating cultured pearls from the queen conch 2Scientists are first to 'unlock' the mystery of creating cultured pearls from the queen conch 3Anadys Pharmaceuticals Inc Announces Strategic Restructuring to Focus Operations on Continuing the Advancement of ANA598 12473 1Anadys Pharmaceuticals Inc Announces Strategic Restructuring to Focus Operations on Continuing the Advancement of ANA598 12473 2Anadys Pharmaceuticals Inc Announces Strategic Restructuring to Focus Operations on Continuing the Advancement of ANA598 12473 3Anadys Pharmaceuticals Inc Announces Strategic Restructuring to Focus Operations on Continuing the Advancement of ANA598 12473 4Anadys Pharmaceuticals Inc Announces Strategic Restructuring to Focus Operations on Continuing the Advancement of ANA598 12473 5Jefferson researchers identify critical marker of response to gemcitabine in pancreatic cancer 47918 1Jefferson researchers identify critical marker of response to gemcitabine in pancreatic cancer 47918 2Scientists discover new genetic immune disorder in children 8716 1Scientists discover new genetic immune disorder in children 8716 2Scientists discover new genetic immune disorder in children 8716 3
... have discovered the first microRNAs tiny bits of...of 10 major degenerative muscular disorders, openi... understanding of these debilitating, poorly under...e published online this week by the Proceedings of... Eisenberg, PhD, of the Program in Genomics at Chi...
... October 17, 2007A late-breaking symposium, Colony...tus, Potential Causes, and Preventive Measures, ha...f the Entomological Society of America (ESA), to b... headed by entomologists Diana Cox-Foster (Penn St...xplore possible factors that may have caused honey...
...n, DC. Ocean Conservancy Scientist, Wallace J. Nic...rcher Hoyt Peckham found surprising results in a r...at Nichols and Peckham conducted over the course o...tober 17 in the online, open-access journal PLoS O... operations are a greater threat to the survival o...
Other Biology News:Massive microRNA scan uncovers leads to treating muscle degeneration 2Research shows loggerhead sea turtles threatened by small-scale fishing operations 2
(Date:11/6/2009)...LLEY, Calif., Nov. 6 Calbiotech, I...ll Business Innovative Research (SBIR) Phase I con...al command. Under terms of the agreement, Calbiote...or the diagnosis of Dengue virus. ,, Dengue ...s a major threat to military forces deployed to tr...
(Date:11/5/2009)...TION -- Gone hybrid . . . , Fuel economy ratin... posted at the www.fueleconomy.gov web site, whi...ntains for the U.S. Department of Energy and the U...op 10 vehicles on the best fuel economy list are h...ity; 48 highway). "This list proves that hybrids h...
(Date:11/5/2009)..., Nov. 5 Imagenetix, Inc... William Spencer, President and CEO of Imagenetix,... annual LD MICRO Conference on Thursday, December ...eles. ,, About LD MICRO ,, LD MICRO is a by-...nding undervalued companies in the micro-cap space...
(Date:11/5/2009)... N.Y., Nov. 5 BioSpecifi...aceutical company developing first-in-class collag...l results for the third quarter ended September 30...eptember of this year, the FDA,s Arthritis Advisor...12-0, the approval of XIAFLEX(TM) for the treatmen...
Breaking Biology Technology:Calbiotech Awarded U.S. Army Phase I SBIR Research Contract to Develop Analyte Specific Reagents for the Diagnosis of Dengue Fever Virus 2November 2009 story tips from the US Department of Energy's Oak Ridge National Laboratory 2November 2009 story tips from the US Department of Energy's Oak Ridge National Laboratory 3Imagenetix to Present at 2nd Annual LD MICRO Conference at the Luxe Sunset Bel Air 2BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results 2BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results 3BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results 4BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results 5
...alif., Sept. 18 InterMune, Inc.,(Nasdaq: ITMN ) ... market,and other conditions, 3,000,000 shares of ...g. The Company expects to grant the underwriters,a...,000 shares of common,stock in connection with the...be sold by InterMune. Goldman, Sachs & Co. is act...
...alif., Sept. 18 Dynavax,Technologies Corporation ...Vice President and Chief Financial Officer, will p...Global Life Sciences Conference in New York, New,Y...n Daylight Savings Time,(6:30 a.m. PDST). The pres...o broadcast and the subsequent archived audio,reco...
...as, Sept. 18 Luminex Corporation,(Nasdaq: LMNX )...he fourth,annual America,s Growth Capital Emerging...in Boston. The investor presentation by Patrick J... and Harriss T. Currie, chief financial officer, w...eptember 20, 2007. The,presentation will be webcas...
Other Biology Technology:InterMune Announces Proposed Public Offering of Common Stock 2Dynavax to Present at UBS 2007 Global Life Sciences Conference 2Luminex Corporation to Present at America's Growth Capital Emerging Growth Conference 2
Anti-IL-12 / IL-23 Monoclonal Antibody, Alexa Fluor 647 Conjugated, Clone C17.8 from eBioscience
Rabbit Anti-Human Naked1 Polyclonal Antibody, Unconjugated from Cell Signaling Technology
Rabbit Anti-Phosphothreonine-X-Phosphotyrosine Polyclonal Antibody, Horseradish Peroxidase Conjugated from Abcam
Rabbit Anti-Human ADAMTS-4, disintegrin-like domain Antibody, Unconjugated from CHEMICON
Biology Products: